A couple things to remember:
1) You can't rush science.
Speaking as someone who has worked on these before, it is important to know that just creating a study design, let alone writing an ethics application for a clinical trial can take months. And that's working fast. Somehow, and I am truly not sure how, our CSO Mark managed to submit clinical trial applications for the Phase 2 clinical trial South Korea COVID study AND the Phase 2 clinical trial idiopathic puplmonary fibrosis study. He did this in a matter of weeks. Again, not sure how, but I am very impressed with that speed. Now... regulatory approval for trials can take weeks as well. I know Algernon said that because of COVID that these things can get approved within days, but I do not think thats reasonable. It does take at least a week or two for the submitting investigators to get feedback from the hospital/health authority and submit revisions. These things almost never simply get accepted first time around. The reason: people's lives are on the line. South Korea is going to be cautious about letting a Canadian Company start running a trial in their neck of the woods. And thats normal and to be expected. Thats why we have our CRO Novotech helping out. Like they said in the recent interviews. They have had 10-15 people working around the clock to get this up and going. We should hear very soon, but investors who have no science background should have patience and remember that this can take time. It will happen. And we will get approval soon.
2. Know the science
Everyone was posting about this Gilead drug and wondering what that means for Algernon. First of all, anyone asking that question at all is showing to the world that they haven't done their due diligence properly and they are undereducated if they are investing in this stock. If you don't know why these things are different, you probably shouldn't be investing. The reason to invest in this stock is the science. The science is legit. So know what the drugs do and then you will feel confident in this company. I'll recap for those who haven't done so... Ifenprodil decreases acute lung injury, this is an endpoint. Acute Lung Injury and Acute Respiratory Distress Syndrome are bad outcomes. So once they have already developed, the severity of how bad they are, determines if the patient lives or dies. Ifenprodil will decrease the severity of this bad outcome. It does this (potentially) by decreasing the inflammatory response which is known to be high (as all the New England Journal of Medicine papers are showing - their is a cytokine storm). The neurons get hyperexcitable and die. The capillaries get leaky in the lungs and they sop with fluid and the patient can't breath. Ifenprodil is an NMDA-antagonist and NMDA is located on the postsynaptic membrane of neurons where if it gets too activated it lets calcium into the neuron and that triggers a death cascade. Mark Williams has said he thinks this drug decreases the hyperinflammatory response. Gilead is working on a drug thats more than a year away from being ready for market. It needs to get tested through a complete phase 3 trial before it would EVER be available for global use and thats at least a year away. The American banks and news use stuff like this to pump the market and try and help halt the global meltdown temporarily but this thing isnt' close to being ready and scientisits and doctors know this. Plus, the mechanism of action is completely different. It works as an anti-viral, helping decrease the rate of replication. Yes this can help patients get better, but patients will still get sick. This isn't a vaccine. Hell, even if we had a vaccine, patients would still get sick because not everyone would get it. So.. end of the day... it has no bearing on our drug and our progress.
